Prognosis of METTL-14 in Endometrial Carcinoma

Launched by ASSIUT UNIVERSITY · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a specific protein called METTL14 in women with type 1 endometrial carcinoma, a common type of uterine cancer. The study aims to understand how the levels of this protein relate to important patient information, like the stage of cancer, the age of the patient, and how well they respond to treatment. Researchers also want to see if the amount of METTL14 in tumor samples can help predict how long patients may stay cancer-free or how long they may live after diagnosis.

To participate in this trial, women must have been diagnosed with type 1 endometrial carcinoma and have had a hysterectomy (surgery to remove the uterus). They also need to have complete medical records available for review, including details about their cancer treatment and follow-up. Unfortunately, if there are gaps in the records or if certain types of samples are not available, those individuals cannot join the study. At this time, the trial is not yet recruiting participants, but it represents an important step in understanding how to improve treatment and outcomes for women with this type of cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Cases of type1endometrial carcinoma with:
• • 1. Hystrectomy operation
• • 2. Available full clinical data about patient (age, complaint, findings in clinical examination).
• • 3. Full data about previous biopsy and radiology.
• • 4. Full data about patient survival, disease progression and history of chemotherapy for three years.
• Exclusion Criteria:
• • 1. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data.
• • 2. Cases with no available H\&E stained slides or formalin fixed paraffin embedded block.
• • 3.D\&C.